COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)						1 Months Ended					3 Months Ended	12 Months Ended
	Jul. 05, 2022	Jun. 06, 2022	May 01, 2022	Oct. 10, 2016	Feb. 10, 2015	Mar. 31, 2023	Jun. 15, 2022	Mar. 23, 2022	Mar. 21, 2022	Jan. 28, 2022	Sep. 27, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 29, 2021	Sep. 30, 2021	Aug. 01, 2018	Feb. 28, 2018	Apr. 27, 2017	Oct. 31, 2016	Sep. 25, 2014
Loss Contingencies [Line Items]
Warrants exercisable per share												$ 0.75	$ 0.75
Compensation increased			$ 25,000
Cash compensation paid												$ 346,846	$ 1,126,481
Exercise bonus													75.00%
Warrants held by trust owned													$ 3,000,000
Warrants and Rights Outstanding												17,778,213
Debt instrument paid amount										$ 2,665,500
Debt Instrument, Interest Rate During Period		25.00%							25.00%	25.00%
Principal, interest		$ 666,375							$ 666,375	$ 666,375
Sale of domain, description								the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.
Loan related to construction															$ 10,010,000
Accrued interest															2,255,802
Total assets												6,360,337	4,341,911		0	$ 297
Total liabilities												7,254,916	15,748,250		10,234,501	10,154,334
Accounts payable and accrued liabilities												1,360,644	570,050		10,009,802	9,939,148
Accounts payable															212,263	214,235
Accrued Liabilities, Current															$ 12,436	$ 950
Gain on legal dissolution of subsidiary												$ 10,234,501
Line of Credit, Current													9,868,495
Weighted average remaining lease term												The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively.
PA-1 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Debt Default, Amount																					$ 8,137,117
Gain (Loss) on Securitization of Financial Assets							$ 104,725
Pennvest Loan [Member]
Loss Contingencies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity												$ 7,754,000
Debt Instrument, Annual Principal Payment												5,886,000
Long-Term Debt, Maturity, Year Two												846,000
Long-Term Debt, Maturity, Year Three												873,000
Long-Term Debt, Maturity, Year Four												149,000
Interest Expense, Debt												$ 123,444	246,887
Subsequent Event [Member]
Loss Contingencies [Line Items]
Debt instrument paid amount											$ 50,000
Aggregate payment	$ 1,996,125
Minimum [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share												$ 0.60
Exercise bonus												50.00%
Maximum [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share												$ 1.50
Exercise bonus												90.00%
Years One Through Five [Member] | Pennvest Loan [Member]
Loss Contingencies [Line Items]
Debt Instrument, Interest Rate During Period												2.547%
Years Six Through Maturity [Member] | Pennvest Loan [Member]
Loss Contingencies [Line Items]
Debt Instrument, Interest Rate During Period												3.184%
Smith [Member]
Loss Contingencies [Line Items]
Cash compensation paid												$ 130,000	$ 139,460
President [Member]
Loss Contingencies [Line Items]
Monthly Officers' Cash Compensation				$ 18,000
Warrants exercisable per share												$ 0.75
President [Member] | Extension Bonus [Member] | FY2016 Extension Agreement [Member]
Loss Contingencies [Line Items]
Deferred Compensation, Maximum Convertible Amount																			$ 300,000	$ 125,000
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)																			$ 0.75	$ 0.75
President [Member] | Warrants Issused, Subscription Receivable [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												300,000		300,000
Warrants exercisable per share												$ 0.60
President [Member] | Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]
Loss Contingencies [Line Items]
Warrants exercisable per share												$ 0.75	$ 0.75
Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Monthly Officers' Cash Compensation					$ 31,000							$ 25,000
Warrants exercisable per share			$ 1.00
Deferred Compensation, Maximum Convertible Amount												10,000
Exercise bonus			75.00%
Number of shares issued			1,000,000
Cancellation of warrants			700,000
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Loss Contingencies [Line Items]
Financing Receivable, after Allowance for Credit Loss, Total												348,643
Repayments of Long-term Debt, Total												$ 250,000	$ 155,000
Chief Executive Officer [Member] | Warrants Issused, Subscription Receivable [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												5,565,000
Chief Executive Officer [Member] | Warrants Expiring on December 31, 2025 [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	3,000,000
Bassani [Member]
Loss Contingencies [Line Items]
Salaries and wages																		$ 31,000
Additional paid amount																		$ 2,000
Bassani [Member] | Forecast [Member]
Loss Contingencies [Line Items]
Interest bearing secured promissory note						$ 300,000